Insider Selling: Oramed Pharmaceuticals (NASDAQ:ORMP) COO Sells $611,020.00 in Stock

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) COO Joshua Hexter sold 137,000 shares of the firm’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.46, for a total value of $611,020.00. Following the completion of the transaction, the chief operating officer owned 1,023,384 shares in the company, valued at approximately $4,564,292.64. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oramed Pharmaceuticals Stock Performance

Oramed Pharmaceuticals stock opened at $4.60 on Friday. The stock has a market cap of $188.28 million, a PE ratio of 1.78 and a beta of 1.21. Oramed Pharmaceuticals Inc. has a one year low of $1.98 and a one year high of $5.19. The stock has a fifty day moving average of $4.11 and a 200 day moving average of $3.63.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Kathmere Capital Management LLC bought a new stake in shares of Oramed Pharmaceuticals during the 1st quarter valued at $51,000. OMERS ADMINISTRATION Corp bought a new position in Oramed Pharmaceuticals in the 1st quarter worth $63,000. Redwood Family Wealth LLC purchased a new position in Oramed Pharmaceuticals during the fourth quarter valued at $66,000. XTX Topco Ltd lifted its position in Oramed Pharmaceuticals by 59.9% during the fourth quarter. XTX Topco Ltd now owns 38,182 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 14,297 shares in the last quarter. Finally, Quadrature Capital Ltd purchased a new position in Oramed Pharmaceuticals during the fourth quarter valued at $119,000. Hedge funds and other institutional investors own 12.73% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Oramed Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, June 11th. One equities research analyst has rated the stock with a Hold rating, According to MarketBeat.com, the stock has a consensus rating of “Hold”.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of proprietary oral drug delivery systems, with an initial emphasis on diabetes management. Headquartered in Jerusalem, Israel, the company leverages its patented protein encapsulation technology, the “Oral Delivery Platform,” to transform injectable therapies into patient-friendly oral formulations. Oramed’s platform is designed to protect sensitive proteins and peptides from degradation in the gastrointestinal tract, enabling successful absorption and systemic delivery.

The company’s lead candidate, ORMD-0801, is an oral insulin capsule for patients with type 2 diabetes, currently advancing through Phase 3 clinical trials.